Stryker Biotech LLC will pay $1.35 million to settle Massachusetts state allegations that the company marketed products for uses not approved by the federal Food and Drug Administration and misled health care providers about the appropriate uses for the products, the Massachusetts Attorney General’s Office announced Aug. 26 (Massachusetts v. Stryker Biotech LLC).
State Attorney General Martha Coakley (D) said in a press release that the settlement marks the culmination of a multiyear investigation into alleged violations of the Massachusetts Consumer Protection Act by the Hopkinton, Mass.-based company.
The act gives the state broad authority to investigate health ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.